JPRN-UMIN000004856已完成1 期
Phase I/II trial of weekly docetaxel and concomitant radiotherapy for unresectable esophageal squamous cell carcinoma after induction chemothrapy - Phase I/II trial of docetaxel and concomitant radiotherapy for unresectable esophageal carcinoma
Gastroenterologic surgery, Kanazawa university0 个研究点目标入组 44 人开始时间: 2011年1月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) The presence of esophageal fistula 2) The presence of severe combined diseases including hear failure, renal failure, hepatic failure and uncontrollable diabetes mellitus. 3) Active infectious diseases (exept HBV or HCV infection). 4) Previous radiotherapy to chest. 5) Apparent interstitial pneumonia or lung fibrosis. 6) Combined active other malignant diseases including simultaneous cancer and disease free state within 5 years after treatment for other cancer except curable intramural cancer by local treatment. 7) The presence of motor paralysis, peripheral neuropathy or edema. 8) No usage of contraceptive method for patients with reproductive age. 9) The presence of mental disease or disorder with difficulty in participating in the clinical trial. 10) Inadequate for clinical trial entry by the attending physicians.
研究者
相似试验
招募中
不适用
Clinical Phase I / II trial of weekly docetaxel therapy in conjunction with radiation in case of FP therapy refractory cases in esophageal cancerEsophageal cancerJPRN-UMIN000030593The Jikei University school of medicine40
已完成
不适用
Phase I/II study of the combination of docetaxel, CDDP and S-1 in patients with unresectable advanced gastric cancerunresectable advanced gastric cancerJPRN-C000000080Fourth Department of Internal Medicine, Sapporo Medical University40
进行中（未招募）
不适用
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - DOCOX GASTRIC (Docetaxel-Oxaliplatin in Gastric Cancer)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-HUSanofi-aventis groupe270
进行中（未招募）
不适用
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - GATE (GAstric cancer study with Taxotere-Eloxatin-based regimens)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-BESanofi-aventis groupe270
进行中（未招募）
不适用
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - DOCOX GASTRIC (Docetaxel-Oxaliplatin in Gastric Cancer)EUCTR2005-005464-92-DESanofi-aventis groupe270